Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Thursday, Morgan Stanley (NYSE:MS) reiterated its Overweight rating and $63.00 price target for Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) shares, representing a significant upside from the current price of $15.04. According to InvestingPro data, analyst targets range from $21 to $75, with the stock currently trading near its 52-week low of $14.69. The firm’s analysis follows Biohaven’s recent Research & Development Day, held on May 28, where management discussed a broad range of progress in the company’s pipeline. The focus was on new data from the degrader platform and advancements in oncology and neuroscience treatment modalities.
Biohaven is actively preparing for the commercial launch of Troriluzole, anticipating a Prescription Drug User Fee Act (PDUFA) decision in the fourth quarter of 2025. With a current ratio of 2.33 and more cash than debt on its balance sheet, the company appears well-positioned to support its diverse pipeline, which includes developments in weight and muscle management through anti-myostatin treatments, inflammation and autoimmune diseases with degraders, neurological conditions via ion channels, and oncology through antibody-drug conjugates (ADCs).
The firm highlighted promising results from Biohaven’s ongoing Phase 1 study of BHV-1300, where the subcutaneous administration showed up to an 87% reduction in immunoglobulin G (IgG), with a median maximum reduction of 83% achieved within 18 days on a 2000mg dose. No clinically significant increases in liver enzymes or reductions in albumin were reported, indicating a favorable tolerance profile for the drug.
Biohaven also presented the potential for adjustable dosing schedules of BHV-1300, which could offer customized treatment regimens for both acute and chronic diseases. The company is planning to initiate a pivotal trial for BHV-1300 in patients with Graves’ disease in the second half of 2025. Morgan Stanley projects that BHV-1300 and BHV-1310 could generate worldwide risk-adjusted sales of approximately $920 million by 2035, accounting for nearly 19% of Biohaven’s total revenue. For a comprehensive analysis of Biohaven’s financial position and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which provides in-depth analysis of the company’s valuation, financial health, and market positioning.
In other recent news, Biohaven Pharmaceutical Holding has made significant strides in its clinical programs and corporate governance. The company held an R&D Day that highlighted promising results from a Phase III trial of BHV-7000, showing a notable reduction in seizures. Additionally, Biohaven’s BHV-1400 demonstrated an 81% reduction in disease-causing proteins in IgA nephropathy, and BHV-1300 showed an 87% reduction in IgG levels in a Phase 1 study. Biohaven is also progressing in oncology, with its BHV-1510 showing positive preliminary results in a Phase 1 trial for advanced cancers.
From an investment perspective, TD Cowen reiterated its Buy rating on Biohaven with a $75 price target, reflecting confidence in the company’s clinical data and growth potential. Meanwhile, RBC Capital Markets lowered its price target to $54 but maintained an Outperform rating, citing potential catalysts in 2025. In corporate news, Biohaven’s shareholders re-elected directors Vlad Coric, M.D., and Kishan Mehta, and ratified Ernst & Young LLP as the company’s auditors. These developments underscore Biohaven’s ongoing efforts to advance its pipeline and maintain strong corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.